摘要
Introduction Hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related mortality.Because HCC typically occurs in patients with advanced liver disease,therapeutic decisions depend on the degree of underlying liver dysfunction and tumor burden.Curative treatment options,which result in 5-year survival rates of 60–80%(surgical resection)and 40–70%(local ablative therapies),are restricted to patients with early-stage HCC(1,2).However,surgical resection and local ablative therapies are limited by high tumor recurrence rates of 50%at 3 years and 70%at 5 years(1-6).Thus,monitoring treatment response is imperative for the clinical management of HCC patients(7),highlighting the need for adjuvant therapies.
